ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men

Phase 3

Withdrawn

Conditions: Hypogonadism
Testosterone Deficiency

Interventions: Drug: ABT-SLV176

First Posted Date: 2014-03-10

Last Posted Date: 2014-06-02

Lead Sponsor: AbbVie

Registration Number: NCT02082197

Locations: 🇺🇸
Site Reference ID/Investigator# 124395, Wichita, Kansas, United States
🇺🇸
Site Reference ID/Investigator# 125782, Mesa, Arizona, United States
🇺🇸
Site Reference ID/Investigator# 123948, Anaheim, California, United States

and more 39 locations

An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications

Phase 3

Completed

Conditions: Advanced Parkinson's Disease

Interventions: Drug: ABT-SLV187

First Posted Date: 2014-03-10

Last Posted Date: 2021-05-12

Lead Sponsor: AbbVie

Target Recruit Count: 30

Registration Number: NCT02082249

Locations: 🇨🇳
Linkou Chang Gung Memorial Ho /ID# 102297, Taoyuan City, Taiwan
🇯🇵
Osaka University Hospital /ID# 108335, Suita-shi, Osaka, Japan
🇯🇵
National Center of Neurology and Psychiatry /ID# 98664, Kodaira, Tokyo, Japan

and more 4 locations

A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

Phase 2

Completed

Conditions: Chronic Hepatitis C
Hepatitis C Virus

Interventions: Drug: ABT-450/ritonavir (r)
Drug: ABT-530
Drug: Ribavirin (RBV)

First Posted Date: 2014-02-21

Last Posted Date: 2018-02-22

Lead Sponsor: AbbVie

Target Recruit Count: 10

Registration Number: NCT02068222

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Drug: Adalimumab
Drug: Placebo

First Posted Date: 2014-02-19

Last Posted Date: 2021-02-18

Lead Sponsor: AbbVie

Target Recruit Count: 514

Registration Number: NCT02065570

Locations: 🇺🇸
Texas Digestive Disease Consultants - Dallas /ID# 138121, Dallas, Texas, United States
🇺🇸
University of Chicago DCAM /ID# 119077, Chicago, Illinois, United States
🇺🇸
Atlanta Gastro Assoc /ID# 119065, Atlanta, Georgia, United States

and more 140 locations

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

Phase 3

Completed

Conditions: Ulcerative Colitis (UC)

Interventions: Drug: Adalimumab
Other: Placebo

First Posted Date: 2014-02-19

Last Posted Date: 2020-11-23

Lead Sponsor: AbbVie

Target Recruit Count: 952

Registration Number: NCT02065622

Locations: 🇺🇸
Atlanta Gastro Assoc /ID# 122336, Atlanta, Georgia, United States
🇺🇸
Northwestern University Feinberg School of Medicine /ID# 122183, Chicago, Illinois, United States
🇺🇸
University of Pittsburgh MC /ID# 122331, Pittsburgh, Pennsylvania, United States

and more 170 locations

A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: Upadacitinib

First Posted Date: 2014-02-19

Last Posted Date: 2021-07-30

Lead Sponsor: AbbVie

Target Recruit Count: 300

Registration Number: NCT02066389

Locations: 🇺🇸
C.V. Mehta MD, Med Corporation /ID# 126380, Hemet, California, United States
🇺🇸
Mountain State Clinical Resear /ID# 127089, Clarksburg, West Virginia, United States
🇿🇦
Panorama Medical Centre /ID# 126846, Cape Town, Western Cape, South Africa

and more 60 locations

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

Phase 3

Completed

Conditions: Ulcerative Colitis

Interventions: Biological: Adalimumab
Biological: Placebo

First Posted Date: 2014-02-19

Last Posted Date: 2020-10-05

Lead Sponsor: AbbVie

Target Recruit Count: 101

Registration Number: NCT02065557

Locations: 🇦🇺
Womens and Childrens Hospital /ID# 127538, Adelaide, South Australia, Australia
🇺🇸
Children's Ctr Digestive, US /ID# 121855, Atlanta, Georgia, United States
🇺🇸
University of Chicago /ID# 120904, Chicago, Illinois, United States

and more 57 locations

Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects

Phase 1

Completed

Conditions: Relative Bioavailability

Interventions: Drug: ABT-333

First Posted Date: 2014-02-03

Last Posted Date: 2014-02-03

Lead Sponsor: AbbVie

Target Recruit Count: 12

Registration Number: NCT02052349

Locations: 🇬🇧
Site Reference ID/Investigator# 118435, Nottingham, United Kingdom

Bioavailability of ABT-450 and ABT-267 With Ritonavir

Phase 1

Completed

Conditions: Absolute Bioavailability

Interventions: Drug: ABT-450/r/ABT-267

First Posted Date: 2014-02-03

Last Posted Date: 2014-02-19

Lead Sponsor: AbbVie

Target Recruit Count: 16

Registration Number: NCT02052362

Locations: 🇬🇧
Site Reference ID/Investigator# 118615, Nottingham, United Kingdom

An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Upadacitinib
Biological: Pneumococcal 13-valent conjugate vaccine (PCV-13)

First Posted Date: 2014-01-30

Last Posted Date: 2022-07-12

Lead Sponsor: AbbVie

Target Recruit Count: 493

Registration Number: NCT02049138

Locations: 🇺🇸
IRIS Research and Development, LLC /ID# 140362, Plantation, Florida, United States
🇨🇱
Quantum Research /ID# 136188, Puerto Varas, Los Lagos, Chile
🇺🇸
The Center for Rheumatology and Bone Research /ID# 124077, Wheaton, Maryland, United States

and more 121 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy